BMRN — Biomarin Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00HealthcareBalancedLarge CapHigh Flyer
- $21.56bn
- $21.37bn
- $1.85bn
- 98
- 14
- 98
- 80
Annual income statement for Biomarin Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,314 | 1,491 | 1,704 | 1,860 | 1,846 |
| Cost of Revenue | |||||
| Gross Profit | 1,072 | 1,176 | 1,345 | 1,336 | 1,376 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,328 | 1,615 | 1,805 | 1,897 | 1,929 |
| Operating Profit | -14.7 | -124 | -100 | -36.8 | -82.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -35.9 | -143 | -94.8 | -42.3 | -75.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -74.7 | -77.2 | -23.8 | 4.56 | -68 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -117 | -77.2 | -23.8 | 859 | -64.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -117 | -77.2 | -23.8 | 859 | -64.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.894 | -0.62 | -0.224 | -0.178 | -0.372 |